Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02553135 · ClinicalTrials.gov registry record · Phase 2
Choroideremia Gene Therapy Clinical Trial
A Phase 2 study of Choroideremia, sponsored by Byron Lam.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT02553135 is a Phase 2 study of Choroideremia that has completed, run by Byron Lam. The registered enrollment target is 6 participants, below the 3,134-participant average among 7 other Choroideremia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02553135, a Phase 2 study of Choroideremia, has completed, sponsored by Byron Lam.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II gene therapy study, involving a total of 6 male patients with choroideremia. The study will be conducted at the Bascom Palmer Eye Institute, University of Miami. Patients will be required to attend a total of 11 study visits over a 24 month period with an additional 3 year follow-up.
Conditions Studied
Interventions
- BIOLOGICAL Injection of AAV2-REP1 (10e11 vg)
Study Locations (1)
Florida
- Bascom Palmer Eye Institute, University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02553135
The ClinicalTrials.gov registry entry for NCT02553135 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,134-participant average among 7 other Choroideremia trials with a reported enrollment target (100% lower). The listed sponsor is Byron Lam, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Choroideremia appearing as the primary indexed condition, and to 1 intervention - of which Injection of AAV2-REP1 (10e11 vg) is the first listed.
NCT02553135 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02553135 about?
NCT02553135 is a clinical study titled "Choroideremia Gene Therapy Clinical Trial". Phase II gene therapy study, involving a total of 6 male patients with choroideremia. The study will be conducted at the Bascom Palmer Eye Institute, University of Miami. Patients will be required to attend a total of 11 study visits over a 24 month period with an additional 3 year follow-up.
What is the current status of trial NCT02553135?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2015-09. Estimated completion is 2018-02.
What conditions does trial NCT02553135 study?
This clinical trial studies the following conditions: Choroideremia.
What interventions are being tested in trial NCT02553135?
The interventions under investigation include: Injection of AAV2-REP1 (10e11 vg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02553135?
This trial is sponsored by Byron Lam, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02553135 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroideremia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High Resolution Retinal Imaging
RECRUITING
-
Inherited Retinal Degenerative Disease Registry
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.